Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0002892 |
Description | A carcinoma arising from the thyroid gland. It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic. [NCIT: C4815] | Trait category |
Cancer
|
Synonyms |
11 synonyms
|
Mapped terms |
12 mapped terms
|
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000087 (CC_Thyroid) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000087/ScoringFiles/PGS000087.txt.gz |
PGS000162 (cGRS_Thyroid) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Thyroid cancer | thyroid carcinoma | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000162/ScoringFiles/PGS000162.txt.gz |
PGS000207 (TC10_Ohio) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000207/ScoringFiles/PGS000207.txt.gz |
PGS000208 (TC10_Iceland) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000208/ScoringFiles/PGS000208.txt.gz |
PGS000209 (TC10_UKB) |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Thyroid cancer | thyroid carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000209/ScoringFiles/PGS000209.txt.gz |
PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000626/ScoringFiles/PGS000626.txt.gz | |
PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000627/ScoringFiles/PGS000627.txt.gz | |
PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 656 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000628/ScoringFiles/PGS000628.txt.gz | |
PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000629/ScoringFiles/PGS000629.txt.gz | |
PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000630/ScoringFiles/PGS000630.txt.gz | |
PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000631/ScoringFiles/PGS000631.txt.gz | |
PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000632/ScoringFiles/PGS000632.txt.gz | |
PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000633/ScoringFiles/PGS000633.txt.gz | |
PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000634/ScoringFiles/PGS000634.txt.gz | |
PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000635/ScoringFiles/PGS000635.txt.gz | |
PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 954 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000636/ScoringFiles/PGS000636.txt.gz | |
PGS000797 (CC_Thyroid_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000797/ScoringFiles/PGS000797.txt.gz |
PGS001289 (GBE_cancer1065) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Thyroid cancer | thyroid carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001289/ScoringFiles/PGS001289.txt.gz |
PGS001354 (PRS12_TC) |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Thyroid cancer | thyroid carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001354/ScoringFiles/PGS001354.txt.gz |
PGS001794 (1kgeur_gbmi_leaveUKBBout_ThC_pst_eff_a1_b0.5_phiauto) |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Thyroid cancer | thyroid carcinoma | 911,462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001794/ScoringFiles/PGS001794.txt.gz |
PGS001799 (1kgeur_gbmi_ThC_pst_eff_a1_b0.5_phiauto) |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Thyroid cancer | thyroid carcinoma | 885,482 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001799/ScoringFiles/PGS001799.txt.gz |
PGS001809 (portability-PLR_193) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Thyroid cancer | thyroid carcinoma | 111 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001809/ScoringFiles/PGS001809.txt.gz |
PGS002018 (portability-ldpred2_193) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Thyroid cancer | thyroid carcinoma | 311,520 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002018/ScoringFiles/PGS002018.txt.gz |
PGS003437 (PRS23_TC) |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Thyroid cancer | thyroid carcinoma | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003437/ScoringFiles/PGS003437.txt.gz |
PGS003746 (PRS11_TC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Thyroid cancer | thyroid carcinoma | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003746/ScoringFiles/PGS003746.txt.gz | |
PGS004954 (PRS26_TC) |
PGP000676 | Pozdeyev N et al. J Clin Endocrinol Metab (2024) |
Thyroid cancer | thyroid carcinoma | 26 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004954/ScoringFiles/PGS004954.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000207 | PGS000087 (CC_Thyroid) |
PSS000126| European Ancestry| 411,118 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Thyroid cancer | OR: 1.55 [1.44, 1.67] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM002052 | PGS000087 (CC_Thyroid) |
PSS001025| European Ancestry| 391,189 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident thyroid cancer | HR: 1.57 [1.36, 1.82] | AUROC: 0.679 C-index: 0.666 (0.023) |
— | Age at assessment, sex,, genotyping array, PCs(1-15), body mass index (BMI <25 vs. 25≤BMI<30, BMI≥30) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM000493 | PGS000162 (cGRS_Thyroid) |
PSS000282| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Thyroid cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.7 [1.29, 2.25] | — | — |
PPM000482 | PGS000162 (cGRS_Thyroid) |
PSS000282| European Ancestry| 13,814 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Thyroid cancer | — | — | Mean realative risk: 1.09 [1.04, 1.15] Wilcoxon test (case vs. control) p-value: 4e-05 |
— | — |
PPM000631 | PGS000207 (TC10_Ohio) |
PSS000342| European Ancestry| 3,137 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.692 [0.673, 0.71] | — | gender, birth year, family history of disease (1st or 2nd degree relative) | AUROC (Clinical factors alone) = 0.585 [0.565 - 0.605] |
PPM017146 | PGS000207 (TC10_Ohio) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |Ext. |
Reported Trait: Thyroid cancer | HR: 1.74 [1.56, 1.94] | AUROC: 0.62 [0.59, 0.64] | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
PPM000632 | PGS000208 (TC10_Iceland) |
PSS000341| European Ancestry| 130,279 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.751 [0.736, 0.768] | — | gender, birth year, family history of disease (1st or 2nd degree relative) | AUROC (Clinical factors alone) = 0.697 [0.680 - 0.714] |
PPM000633 | PGS000209 (TC10_UKB) |
PSS000343| European Ancestry| 408,479 individuals |
PGP000085 | Liyanarachchi S et al. Proc Natl Acad Sci U S A (2020) |
Reported Trait: Thyroid cancer | — | AUROC: 0.694 [0.673, 0.716] | — | gender, birth year | AUROC (Clinical factors alone) = 0.629 [0.606 - 0.651] |
PPM001311 | PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.161 [1.048, 1.285] β: 0.149 (0.052) |
AUROC: 0.529 [0.496, 0.559] | Nagelkerke's Pseudo-R²: 0.0041 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.18, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608 |
PPM001312 | PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.27 [1.148, 1.405] β: 0.239 (0.0515) |
AUROC: 0.56 [0.53, 0.59] | Nagelkerke's Pseudo-R²: 0.0107 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.17, 4.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608 |
PPM001313 | PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.276 [1.155, 1.41] β: 0.244 (0.0509) |
AUROC: 0.565 [0.535, 0.595] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 1.91 [0.861, 4.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608 |
PPM001314 | PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | β: 0.114 (0.0517) OR: 1.121 [1.013, 1.24] |
AUROC: 0.52 [0.488, 0.55] | Nagelkerke's Pseudo-R²: 0.00247 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.15 [1.01, 4.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C73_PT_MGI_20200608 |
PPM001315 | PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.598 [1.439, 1.775] β: 0.469 (0.0536) |
AUROC: 0.626 [0.597, 0.655] | Nagelkerke's Pseudo-R²: 0.0393 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.53 [1.87, 6.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608 |
PPM021099 | PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PSS011527| Multi-ancestry (including European)| 359 individuals |
PGP000610 | Wang JR et al. J Clin Endocrinol Metab (2023) |Ext. |
Reported Trait: BRAFV600E tumor driver subtype in individuals with papillary thyroid carcinoma | OR: 1.51 [1.09, 2.08] | — | — | — | — |
PPM001316 | PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.651 [1.41, 1.934] β: 0.501 (0.0806) |
AUROC: 0.636 [0.589, 0.682] | Nagelkerke's Pseudo-R²: 0.0478 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.4 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608 |
PPM001317 | PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.568 [1.412, 1.74] β: 0.45 (0.0532) |
AUROC: 0.618 [0.587, 0.647] | Nagelkerke's Pseudo-R²: 0.0365 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 5.14 [2.94, 8.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608 |
PPM001318 | PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.609 [1.38, 1.876] β: 0.476 (0.0783) |
AUROC: 0.628 [0.582, 0.675] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0804 Odds Ratio (OR, top 1% vs. Rest): 4.41 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608 |
PPM001319 | PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.119 [1.008, 1.241] β: 0.112 (0.053) |
AUROC: 0.535 [0.504, 0.567] | Nagelkerke's Pseudo-R²: 0.00228 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.562, 3.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608 |
PPM001320 | PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.315 [1.194, 1.448] β: 0.274 (0.0492) |
AUROC: 0.569 [0.538, 0.598] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.65 [0.708, 3.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608 |
PPM001321 | PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.385 [1.254, 1.529] β: 0.325 (0.0507) |
AUROC: 0.578 [0.548, 0.607] | Nagelkerke's Pseudo-R²: 0.0205 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 3.21 [1.67, 6.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608 |
PPM002068 | PGS000797 (CC_Thyroid_IV) |
PSS001025| European Ancestry| 391,189 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident thyroid cancer | HR: 1.75 [1.53, 2.01] | AUROC: 0.701 C-index: 0.692 (0.022) |
R²: 0.31 | Age at assessment, sex,, genotyping array, PCs(1-15), body mass index (BMI <25 vs. 25≤BMI<30, BMI≥30) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM008943 | PGS001289 (GBE_cancer1065) |
PSS007656| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.72837 [0.59989, 0.85685] | R²: 0.0395 Incremental AUROC (full-covars): 0.01385 PGS R2 (no covariates): 0.0141 PGS AUROC (no covariates): 0.6101 [0.46446, 0.75575] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008944 | PGS001289 (GBE_cancer1065) |
PSS007657| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.83233 [0.67782, 0.98683] | R²: 0.16699 Incremental AUROC (full-covars): -0.00184 PGS R2 (no covariates): 0.01024 PGS AUROC (no covariates): 0.54057 [0.24283, 0.83831] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008945 | PGS001289 (GBE_cancer1065) |
PSS007658| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.71465 [0.65621, 0.77309] | R²: 0.04643 Incremental AUROC (full-covars): 0.00897 PGS R2 (no covariates): 0.00455 PGS AUROC (no covariates): 0.55967 [0.48236, 0.63699] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008946 | PGS001289 (GBE_cancer1065) |
PSS007659| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.71171 [0.57425, 0.84917] | R²: 0.04277 Incremental AUROC (full-covars): 0.00229 PGS R2 (no covariates): 0.00022 PGS AUROC (no covariates): 0.51375 [0.35907, 0.66843] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008947 | PGS001289 (GBE_cancer1065) |
PSS007660| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Thyroid cancer | — | AUROC: 0.63744 [0.5901, 0.68478] | R²: 0.016 Incremental AUROC (full-covars): 0.03389 PGS R2 (no covariates): 0.01236 PGS AUROC (no covariates): 0.61843 [0.56413, 0.67273] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM005178 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors | — | — | Relative Rate (RR): 1.57 [1.24, 1.98] | Attained age modeled by restricted cubic splines | — |
PPM005179 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had received neck radiotherapy | — | — | Relative Rate (RR): 1.68 [1.29, 2.18] | Attained age modeled by restricted cubic splines | — |
PPM005180 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors | — | — | Relative Rate (RR): 1.52 [1.25, 1.83] | Attained age modeled by restricted cubic splines | — |
PPM005181 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had received neck radiotherapy | — | — | Relative Rate (RR): 1.42 [1.09, 1.85] | Attained age modeled by restricted cubic splines | — |
PPM005182 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors who had not received neck radiotherapy | — | — | Relative Rate (RR): 1.66 [1.26, 2.2] | Attained age modeled by restricted cubic splines | — |
PPM005183 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 40 | — | AUROC: 0.83 C-index: 0.842 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
PPM005184 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 40 | — | AUROC: 0.73 C-index: 0.73 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
PPM005185 | PGS001354 (PRS12_TC) |
PSS003603| European Ancestry| 2,370 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 50 | — | AUROC: 0.82 C-index: 0.834 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
PPM005186 | PGS001354 (PRS12_TC) |
PSS003602| European Ancestry| 6,416 individuals |
PGP000251 | Song N et al. Cancer Epidemiol Biomarkers Prev (2021) |
Reported Trait: Subsequent thyroid cancer in childhood cancer survivors aged 50 | — | AUROC: 0.72 C-index: 0.727 |
— | Clincial model (age at diagnosis, attained age modeled by restricted cubic splines, sex, combined treatment group) | — |
PPM009298 | PGS001794 (1kgeur_gbmi_leaveUKBBout_ThC_pst_eff_a1_b0.5_phiauto) |
PSS007717| European Ancestry| 358,476 individuals |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Reported Trait: Thyroid cancer | — | AUROC: 0.676 | Nagelkerke's R2 (covariates regressed out): 0.01366 | sex,age,age2,age*sex,age^2*sex, 20PCs | — |
PPM009315 | PGS001799 (1kgeur_gbmi_ThC_pst_eff_a1_b0.5_phiauto) |
PSS007697| European Ancestry| 7,128 individuals |
PGP000262 | Wang Y et al. Cell Genom (2023) |
Reported Trait: Thyroid cancer | — | AUROC: 0.685 | Nagelkerke's R2 (covariates regressed out): 0.01036 | sex,age, 20PCs | — |
PPM009374 | PGS001809 (portability-PLR_193) |
PSS009279| European Ancestry| 19,923 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0307 [0.0168, 0.0446] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009377 | PGS001809 (portability-PLR_193) |
PSS008383| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0014 [-0.0586, 0.0557] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009378 | PGS001809 (portability-PLR_193) |
PSS008161| South Asian Ancestry| 6,305 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0052 [-0.0195, 0.0299] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009379 | PGS001809 (portability-PLR_193) |
PSS007948| East Asian Ancestry| 1,801 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0121 [-0.0585, 0.0344] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009380 | PGS001809 (portability-PLR_193) |
PSS007730| African Ancestry| 2,453 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0102 [-0.0296, 0.0499] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009381 | PGS001809 (portability-PLR_193) |
PSS008833| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0008 [-0.0307, 0.0323] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009375 | PGS001809 (portability-PLR_193) |
PSS009053| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0082 [-0.0388, 0.0225] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009376 | PGS001809 (portability-PLR_193) |
PSS008607| European Ancestry| 6,640 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0196 [-0.0045, 0.0437] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011018 | PGS002018 (portability-ldpred2_193) |
PSS009279| European Ancestry| 19,923 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0295 [0.0157, 0.0434] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011019 | PGS002018 (portability-ldpred2_193) |
PSS009053| European Ancestry| 4,120 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0056 [-0.0362, 0.0251] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011020 | PGS002018 (portability-ldpred2_193) |
PSS008607| European Ancestry| 6,640 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0208 [-0.0033, 0.0448] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011021 | PGS002018 (portability-ldpred2_193) |
PSS008383| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.0107 [-0.0677, 0.0465] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011022 | PGS002018 (portability-ldpred2_193) |
PSS008161| South Asian Ancestry| 6,305 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0149 [-0.0098, 0.0396] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011023 | PGS002018 (portability-ldpred2_193) |
PSS007948| East Asian Ancestry| 1,801 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): -0.004 [-0.0505, 0.0424] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011024 | PGS002018 (portability-ldpred2_193) |
PSS007730| African Ancestry| 2,453 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0184 [-0.0213, 0.0581] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011025 | PGS002018 (portability-ldpred2_193) |
PSS008833| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Thyroid cancer | — | — | Partial Correlation (partial-r): 0.0029 [-0.0286, 0.0343] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM017148 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x total moderate to vigorous physical activity interaction | HR: 0.74 [0.57, 0.97] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
PPM017149 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x smoke intake interaction | HR: 0.48 [0.32, 0.72] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
PPM017145 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Thyroid cancer | HR: 1.95 [1.68, 2.26] | AUROC: 0.64 [0.61, 66.0] | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
PPM017147 | PGS003437 (PRS23_TC) |
PSS010136| European Ancestry| 264,956 individuals |
PGP000439 | Feng X et al. JAMA Netw Open (2022) |
Reported Trait: Incident thyroid cancer x healthy lifestyle interaction | HR: 0.52 [0.37, 0.73] | — | — | age, sex, and genetic composition, townsend deprivation index at recruitment, qualifications and average total household income before tax | — |
PPM018502 | PGS003746 (PRS11_TC) |
PSS010996| European Ancestry| 360 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Thyroid cancer | OR: 1.63 [1.44, 1.85] | — | — | — | — |
PPM021769 | PGS004954 (PRS26_TC) |
PSS011791| Multi-ancestry (including European)| 73,346 individuals |
PGP000676 | Pozdeyev N et al. J Clin Endocrinol Metab (2024) |
Reported Trait: Thyroid cancer | — | AUROC: 0.7 | — | Age, sex, genotyping batch, 10 PCs | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000558 | PheCode:193; ICD9CM:193, V10.87; ICD10CM:C73 | — | [
|
— | European | — | MGI | — |
PSS000126 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 32010 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
PSS003602 | All individuals were childhood cancer survivors. Of the 6,414 childhood cancer survivors, 1,374 had received neck radiotherapy (neck-RT) as a form of treatment. Cases were individuals who developed subsequent thyroid cancer (STC). Cases of STC were ascertained by self-report questionnaires and subsequently confirmed by pathology reports. 73 of the 121 STC cases had received neck-RT as a form of childhood cancer treatment, whilst 48 had not. Of the controls, 1,301 had received neck-RT as a form of childhood cancer treatment. | Median = 36.5 years | [ ,
47.7 % Male samples |
— | European | — | NR | — |
PSS003603 | All individuals were childhood cancer survivors. Of the 2,370 childhood cancer survivors, 476 had received neck radiotherapy (neck-RT) as a form of treatment. Cases were individuals who developed subsequent thyroid cancer (STC). Cases of STC were clinically ascertained. 47 of the 65 STC cases had received neck-RT as a form of childhood cancer treatment, whilst 18 had not. | Median = 36.6 years IQR = [30.3, 44.1] years |
[ ,
53.4 % Male samples |
— | European | — | SJCRH | — |
PSS008383 | — | — | 1,197 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
PSS010996 | — | — | 360 individuals | Mean = 48.04 years | European | — | TCGA | — |
PSS000579 | PheCode:193; ICD9:193; ICD10:C73 | — | [
|
— | European | — | UKB | — |
PSS009053 | — | — | 4,120 individuals | — | European | Poland (NE Europe) | UKB | — |
PSS008161 | — | — | 6,305 individuals | — | South Asian | India (South Asia) | UKB | — |
PSS007656 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS007657 | — | — | [
|
— | East Asian | — | UKB | — |
PSS007658 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
PSS007659 | — | — | [
|
— | South Asian | — | UKB | — |
PSS007660 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
PSS011791 | — | — | 73,346 individuals | — | African American or Afro-Caribbean, Asian unspecified, European, Native American, Not reported | — | CCPM | — |
PSS007697 | — | — | [
|
— | European | — | CanPath | — |
PSS008833 | — | — | 3,896 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
PSS010136 | — | — | [
|
— | European | — | UKB | — |
PSS007948 | — | — | 1,801 individuals | — | East Asian | China (East Asia) | UKB | — |
PSS007717 | — | — | [
|
— | European | — | UKB | — |
PSS008607 | — | — | 6,640 individuals | — | European | Italy (South Europe) | UKB | — |
PSS000282 | Primary tumor samples from TCGA | — | [
|
Mean = 49.0 years Sd = 16.0 years |
European | — | TCGA | — |
PSS000282 | — | — | [
|
— | European | — | eMERGE | — |
PSS011527 | — | — | 245 individuals | — | European | — | TCGA | — |
PSS011527 | — | — | 30 individuals | — | Asian unspecified | — | TCGA | — |
PSS011527 | — | — | 13 individuals | — | African American or Afro-Caribbean | — | TCGA | — |
PSS011527 | — | — | 71 individuals | — | Not reported | — | TCGA | — |
PSS007730 | — | — | 2,453 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
PSS000341 | Cases were ascertained using ICD-10 C73 (PTC, FTC, cancer/carcinoma, and rare nonmedullary) | — | [ ,
46.41 % Male samples |
— | European | — | deCODE | — |
PSS000342 | Histologically confirmed papillary or follicular thyroid carcinoma (PTC) patients (including traditional PTC and follicular variant PTC) | — | [ ,
26.08 % Male samples |
— | European | — | NR | — |
PSS000343 | Cases were ascertained using ICD-10 C73 (PTC, FTC, cancer/carcinoma, and rare nonmedullary) | — | [ ,
45.97 % Male samples |
— | European | — | UKB | — |
PSS009279 | — | — | 19,923 individuals | — | European | UK (+ Ireland) | UKB | — |
PSS001025 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |